Search results for "MESH: Prospective Studies"

showing 7 items of 17 documents

Normal Reference Ranges for Echocardiography: Rationale, study design, and methodology (NORRE Study)

2013

International audience; BACKGROUND: Availability of normative reference values for cardiac chamber dimensions, volumes, mass, and function is a prerequisite for the accurate application of echocardiography for both clinical and research purposes. However, due to the lack of consistency in current echocardiographic 'reference values', their use for clinical decision-making remains questionable. AIMS: The aim of the 'Normal Reference Ranges for Echocardiography Study (NORRE Study)' is to obtain a set of 'normal values' for cardiac chamber geometry and function in a large cohort of healthy Caucasian individuals aged over a wide range of ages (25-75 years) using both conventional and advanced e…

MaleRadiology Nuclear Medicine and ImagingMESH: Echocardiography DopplerLeftSex Factor030204 cardiovascular system & hematologyDoppler echocardiographyDoppler imagingMESH: Stroke VolumeMESH: Ventricular Function LeftVentricular Function Left030218 nuclear medicine & medical imagingHeart VentricleCohort Studies0302 clinical medicine[INFO.INFO-TS]Computer Science [cs]/Signal and Image ProcessingNuclear Medicine and ImagingVentricular FunctionAge FactorProspective StudiesProspective cohort studyMESH: Cohort StudiesMESH: Aged2D and 3D echocardiographyMESH: Middle Agedmedicine.diagnostic_testAnthropometryAge FactorsDopplerGeneral MedicinePulsedReference Standardsreference valuesMiddle AgedCardiac mechanicEchocardiography Doppler3. Good healthEuropeMESH: Echocardiography Doppler PulsedCardiac mechanicsEchocardiographyMESH: Reference Standards[SDV.IB]Life Sciences [q-bio]/BioengineeringFemaleRadiologyCardiology and Cardiovascular Medicine[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processingCohort study2D and 3D echocardiography; Cardiac mechanics; Chamber size and function; M-mode; reference values; Adult; Age Factors; Aged; Anthropometry; Cohort Studies; Echocardiography Doppler; Echocardiography Doppler Pulsed; Europe; Female; Heart Ventricles; Humans; Male; Middle Aged; Prospective Studies; Reference Standards; Sensitivity and Specificity; Sex Factors; Stroke Volume; Ventricular Function Left; Cardiology and Cardiovascular Medicine; Radiology Nuclear Medicine and ImagingHumanAdultmedicine.medical_specialtyHeart VentriclesM-modeChamber size and functionSensitivity and Specificity03 medical and health sciencesSex FactorsMESH: Sex FactorsMESH: Anthropometry[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansMedical physicsAgedMESH: Age FactorsEchocardiography Doppler PulsedReproducibilityMESH: Humansbusiness.industryreference valueMESH: AdultStroke VolumeMESH: MaleMESH: Prospective StudiesMESH: Sensitivity and SpecificitySurgeryClinical trialProspective StudieSample size determinationReference StandardObservational studyMESH: EuropeMESH: Heart VentriclesCohort StudiebusinessMESH: Female
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxe…

2010

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.From 2005 to 2010, patients with HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered. Twenty-three patients received 50 mg cyclophosphamide and 10 mg prednisolone per os daily until disease progression. Treatment tolerance and efficacy on PSA decrease and pain were studied.Metronomic cyclophospham…

Male[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : Antineoplastic Combined Chemotherapy ProtocolsMESH: Treatment FailurePrednisoloneMESH : MaleMESH : PrednisoloneMESH: TaxoidsMESH : AgedMESH : Prospective StudiesDocetaxelMESH : Treatment OutcomeMESH : Treatment FailureMESH: Aged 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumans[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : Middle AgedProspective StudiesTreatment FailureMESH : Prostate-Specific AntigenMESH : Aged 80 and overMESH : TaxoidsCyclophosphamideMESH : Cyclophosphamidehealth care economics and organizationsAgedMESH: Treatment OutcomeAged 80 and overMESH: AgedMESH: HumansMESH: Middle AgedMESH : HumansProstatic NeoplasmsMESH: CyclophosphamideMiddle AgedProstate-Specific AntigenMESH: MaleMESH: Prospective StudiesMESH: Prostate-Specific AntigenMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeMESH: Prostatic Neoplasms[SDV.IMM]Life Sciences [q-bio]/ImmunologyTaxoidsMESH: PrednisoloneMESH : Prostatic Neoplasms
researchProduct

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with adv…

2012

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was a result of the combination of pertuzumab and trastuzumab or of pertuzumab alone, we recruited a third cohort of patients who received pertuzumab without trastuzumab. We then investigated the impact of reintroducing trastuzumab to patients whose disease progressed on pertuzumab monotherapy. Patients and Methods Twenty-nine patients with HER2-positive breast cancer whose d…

OncologyCancer ResearchReceptor ErbB-2MESH: Risk AssessmentMESH: Dose-Response Relationship Drug0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesProspective cohort studyskin and connective tissue diseasespertuzumab; trastuzumab; breast cancerMESH: Treatment OutcomeMESH: Aged0303 health sciencesMESH: Middle AgedMESH: ErythrocytesAge FactorsMESH: Maximum Tolerated DoseMESH: Neoplasm StagingMiddle AgedPrognosis3. Good healthtrastuzumabMESH: Antineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeOncologyTolerabilityMESH: Receptor erbB-2030220 oncology & carcinogenesisMESH: Survival AnalysisDisease Progression[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Disease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialty[SDV.IMM] Life Sciences [q-bio]/ImmunologyMaximum Tolerated DoseMESH: Blood TransfusionBreast NeoplasmsMESH: Drug Administration ScheduleAntibodies Monoclonal HumanizedLoading doseMESH: Cell SeparationRisk AssessmentMESH: PrognosisDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesbreast cancerBreast cancerMESH: PrionspertuzumabInternal medicineHumansMESH: Patient SelectionNeoplasm InvasivenessneoplasmsSurvival analysis030304 developmental biologyAgedNeoplasm StagingMESH: Age FactorsMESH: HumansDose-Response Relationship Drugbusiness.industryPatient SelectionMESH: AdultMESH: Neoplasm InvasivenessMESH: Creutzfeldt-Jakob SyndromeTrastuzumabmedicine.diseaseSurvival AnalysisMESH: Prospective StudiesMESH: Antibodies Monoclonal HumanizedMESH: Disease-Free SurvivalbusinessMESH: FemaleProgressive diseaseMESH: Breast NeoplasmsJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo.

2011

International audience; BACKGROUND AND OBJECTIVES: Interaction of bacteria with the immune system within the intestinal mucosa plays a key role in the pathogenesis of inflammatory bowel disease (IBD). The aim of the current study was to develop a fluorescein-aided confocal laser endomicroscopy (CLE) method to visualise intramucosal enteric bacteria in vivo and to determine the involved mucosal area in the colon and ileum in patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Initially, E coli strains expressing enhanced green fluorescent protein (pEGFP) were endomicroscopically imaged in mice. In addition, ex vivo and in vivo imaging of fluorescent human enteric bacteri…

PathologyMESH : Escherichia colifluoresceinMESH : Retrospective StudiesColorectal cancerMESH : Prospective StudiesGastroenterologyInflammatory bowel disease[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineIntestinal mucosaMESH: Microscopy ConfocalMESH: AnimalsMESH : Colonoscopy1506MESH: In Situ Hybridization Fluorescenceintramucosal bacteria0303 health sciencesCrohn's diseaseMESH: Escherichia coliGastroenterologyMESH : EnterobacteriaceaeMESH : Colitis UlcerativeUlcerative colitisenteric bacterial microflora3. Good healthMESH : In Situ Hybridization FluorescenceCrohn's diseaseMESH: Colonoscopyconfocal laser endomicroscopyMESH: Intestinal MucosaMESH : Inflammatory Bowel Diseases030211 gastroenterology & hepatologymedicine.medical_specialtyMESH : MaleMESH: Colitis Ulcerative[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Mice Inbred C57BLBiologyMESH : Intestinal MucosaMESH : Crohn Disease03 medical and health sciencesMESH: EnterobacteriaceaeFISHfluorescence endoscopyIn vivoMESH: Mice Inbred C57BLInternal medicineMESH : MicemedicineEndomicroscopyMESH: ColonMESH : Microscopy ConfocalMESH: Miceulcerative colitis030304 developmental biologyMESH : IleumMESH: HumansBacteriaMESH: Crohn Diseaseinfectious colitisMESH : HumansEndoscopyMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesMESH : ColonMESH: MaleMESH: Prospective StudiesMESH: IleumMESH : AnimalsEx vivo
researchProduct

Childhood maltreatment and clinical severity of treatment‐resistant depression in a French cohort of outpatients (FACE‐DR): One‐year follow‐up

2020

International audience; Childhood maltreatment is associated with major depressive disorder (MDD). It not only increases the risk of lifetime MDD, but it also aggravates its course. Among depressed patients, 20-30% of them experience treatment-resistance depression (TRD). We aimed to assess the association between childhood maltreatment, severity of depression in a unipolar TRD sample, and patient outcomes after one-year of follow-up. Methods: Patients were recruited for a prospective cohort from the French network of TRD expert centers. Depressive symptom severity was assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology se…

medicine.medical_specialtyDepressive disordersMESH: DepressionPopulationMESH: Depressive Disorder MajorPoison controlChildhood trauma03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesMESH: ChildOutpatientsmedicineHumansChild AbuseProspective StudiesMESH: Surveys and QuestionnaireseducationProspective cohort studyChildChildhood neglecteducation.field_of_studyDepressive Disorder Major[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsMESH: Humansbusiness.industryDepressionAntidepressant responseChildhood abuseCTQ treeMESH: Follow-Up StudiesMESH: Child Abusemedicine.diseaseMESH: Prospective Studies3. Good health030227 psychiatryMESH: OutpatientsPsychiatry and Mental healthClinical PsychologySexual abuse[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthCohortMajor depressive disorderTreatment-resistant depressionbusinessTreatment-resistant depression030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, ra…

2021

International audience; BACKGROUND: Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. METHODS: This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined …

medicine.medical_specialtyMESH: Acute Kidney Injury[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulation030204 cardiovascular system & hematologyurologic and male genital diseasesMESH: Severity of Illnes Index03 medical and health sciencesMESH: Aged 80 and over0302 clinical medicineOliguriaIntensive careInternal medicineMedicineMESH: Time-to-Treatment030212 general & internal medicineRenal replacement therapyeducationBlood urea nitrogenMESH: Agededucation.field_of_studyMESH: HumansMESH: Middle Agedbusiness.industryHazard ratioAcute kidney injuryGeneral Medicinemedicine.diseaseMESH: MaleMESH: Prospective Studies3. Good health[SDV] Life Sciences [q-bio]MESH: FranceMESH: Intensive Care Unitsmedicine.symptomMESH: Renal Remplacement TherapybusinessMESH: FemaleKidney diseaseThe Lancet
researchProduct